Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment.

Cell death & disease·2026
Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Electrochemical Detection of Neuronal Injury in Cell Culture Samples: A Cost-Effective Biosensor for Neurofilament Light Sensing.

Biosensors·2026
Same author

Different contributions of YAP1 and TAZ in the regulation of GIST tumorigenic properties.

Cell communication and signaling : CCS·2026
Same author

Correction: Investigating the role of EGFR signalling in muscle dystrophies: implications for Duchenne muscular dystrophy.

Cell death & disease·2026
Same author

First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas.

Annals of surgical oncology·2026
Same journal

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.

NPJ precision oncology·2026
Same journal

From tumor regression grading to interpretable endpoints in neoadjuvant oncology.

NPJ precision oncology·2026
Same journal

Mutation enrichment in targeted panels flags immunotherapy-responsive POLE-driven hypermutated microsatellite-stable colorectal cancers.

NPJ precision oncology·2026
Same journal

Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study.

NPJ precision oncology·2026
Same journal

Anatomically constrained deep learning for clinical-grade volumetric pancreatic cancer segmentation: development, validation, and architectural benchmarking.

NPJ precision oncology·2026
Same journal

Pan-cancer analysis of tissue-plasma genomic concordance reveals enhanced concordance with liver metastasis and plasma clonality as predictor of poorer overall survival.

NPJ precision oncology·2026
See all related articles

Related Experiment Video

Updated: Aug 19, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.7K

Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy.

Albert Manzano-Muñoz1, José Yeste2, María A Ortega2,3

  • 1Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

NPJ Precision Oncology
|December 1, 2022
PubMed
Summary
This summary is machine-generated.

A new microfluidic dynamic BH3 profiling (µDBP) assay reduces cell requirements for predicting anticancer drug efficacy. This innovation aids precision medicine by enabling faster, scalable drug screening on patient samples, including solid tumors.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.8K

Related Experiment Videos

Last Updated: Aug 19, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.8K

Area of Science:

  • Oncology
  • Biotechnology
  • Molecular Biology

Background:

  • Precision medicine increasingly uses functional assays to guide anticancer therapy selection.
  • Dynamic BH3 profiling (DBP) predicts treatment efficacy by measuring apoptotic priming but requires substantial cell numbers.
  • High cell number requirements limit DBP's application in patient-derived solid tumor samples.

Purpose of the Study:

  • To develop and validate a microfluidic-based DBP (µDBP) assay to overcome cell number limitations.
  • To assess µDBP's capacity to predict anticancer agent efficacy using gastrointestinal stromal tumor (GIST) models.
  • To evaluate µDBP on a refractory GIST patient sample for personalized treatment prediction.

Main Methods:

  • Development of a microfluidic chip for DBP using a BIM BH3 peptide gradient.
  • Comparison of µDBP with standard flow cytometry-based DBP.
  • Testing of µDBP with imatinib-sensitive and resistant GIST cell lines and a refractory GIST patient sample.
  • Evaluation of anticancer treatments, including dactolisib and venetoclax combination therapy.

Main Results:

  • µDBP successfully detected differences in apoptotic priming between sensitive and resistant GIST cell lines.
  • The assay accurately anticipated treatment-induced cytotoxicity.
  • µDBP analysis of a patient sample indicated that dactolisib and venetoclax combination therapy enhanced apoptotic priming.

Conclusions:

  • Microfluidic DBP (µDBP) is a scalable, user-friendly assay that overcomes cell number limitations of standard DBP.
  • µDBP holds significant potential for advancing precision medicine by enabling routine in situ drug screening for personalized cancer treatment.
  • This technology can facilitate rapid identification of effective anticancer agents for individual patients.